Alistair Milnes Biography and Net Worth

Alistair Milnes is chief operating officer at Bicycle Therapeutics.

Alistair joined Bicycle Therapeutics from Rio Tinto, the global commodities giant, where he acted as a strategic adviser, spanning transformation, people and communications for its commercial business based in Singapore and with operations across five continents.

Prior to Rio, he led communications and human resources at GM&T, a multinational energy trading company with an award-winning retail business. Reporting to the CEO, and as part of the leadership team, he was instrumental in the development and growth of the organization in new territories and markets, quadrupling the headcount, and growing revenues from double digit millions to £80 billion. Before GM&T, Alistair led business and brand development at Hodes, an Omnicom company, advising clients on brand and growth strategies.

Alistair was a consultant to Bicycle before joining full-time in January 2021 to lead communications and human resources. Alistair was appointed COO in January 2022.

What is Alistair Milnes' net worth?: The estimated net worth of Alistair Milnes is at least $666.71 thousand as of October 3rd, 2025. Milnes owns 93,377 shares of Bicycle Therapeutics stock worth more than $666,712 as of December 5th. This net worth estimate does not reflect any other investments that Milnes may own. Additionally, Milnes receives a salary of $796,090.00 as COO at Bicycle Therapeutics. Learn More about Alistair Milnes' net worth.
How old is Alistair Milnes?: Milnes is currently 50 years old. There are 6 older executives and no younger executives at Bicycle Therapeutics. The oldest executive at Bicycle Therapeutics is Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director, who is 73 years old. Learn More on Alistair Milnes' age.
What is Alistair Milnes' salary?: As the COO of Bicycle Therapeutics PLC Sponsored ADR, Milnes earns $796,090.00 per year. There are 3 executives that earn more than Milnes. The highest earning executive at Bicycle Therapeutics is Dr. Kevin Lee M.B.A., Ph.D., CEO & Executive Director, who commands a salary of $1,350,000.00 per year. Learn More on Alistair Milnes' salary.
How do I contact Alistair Milnes?: The corporate mailing address for Milnes and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Alistair Milnes' contact information.
Has Alistair Milnes been buying or selling shares of Bicycle Therapeutics?: In the last ninety days, Alistair Milnes has sold $17,859.78 in shares of Bicycle Therapeutics stock. Most recently, Alistair Milnes sold 978 shares of the business's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $8.41, for a transaction totalling $8,224.98. Following the completion of the sale, the chief operating officer now directly owns 93,377 shares of the company's stock, valued at $785,300.57. Learn More on Alistair Milnes' trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Santiago Arroyo (Insider), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), Pierre Legault (Director), Alistair Milnes (COO), Michael Skynner (CTO), Travis Thompson (CAO), and Alethia Young (CFO). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, Bicycle Therapeutics insiders bought shares 2 times. They purchased a total of 1,485,397 shares worth more than $21,229,062.72. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 49,366 shares worth more than $563,681.34. The most recent insider tranaction occured on October, 3rd when CEO Kevin Lee sold 3,231 shares worth more than $27,172.71. Insiders at Bicycle Therapeutics own 22.9% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 10/3/2025.

Alistair Milnes Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/3/2025	Sell	978	$8.41	$8,224.98	93,377
10/2/2025	Sell	1,147	$8.40	$9,634.80	94,355
7/3/2025	Sell	966	$7.44	$7,187.04	95,502
7/2/2025	Sell	1,149	$7.09	$8,146.41	96,468
4/2/2025	Sell	1,133	$8.02	$9,086.66	98,655
1/2/2025	Sell	4,578	$14.09	$64,504.02	100,724
10/3/2023	Sell	442	$20.00	$8,840.00	36,839

Alistair Milnes Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $7.14

$6.96

$7.27

50 Day Range

MA: $7.48

$6.17

$8.87

2 Week Range

Now: $7.14

$6.03

$21.50

Volume

302,559 shs

Average Volume

327,116 shs

Market Capitalization

$495.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Alistair Milnes Biography and Net Worth

What is Alistair Milnes' net worth?

How old is Alistair Milnes?

What is Alistair Milnes' salary?

How do I contact Alistair Milnes?

Has Alistair Milnes been buying or selling shares of Bicycle Therapeutics?

Who are Bicycle Therapeutics' active insiders?

Are insiders buying or selling shares of Bicycle Therapeutics?